A name that was wrong for decades, finally corrected
For generations, a condition shaping the lives of one in eight women was defined by what it appeared to be rather than what it truly was — a name built on a misreading that quietly delayed care for millions. Now, an international consensus of 56 organizations has formally corrected the record, renaming Polycystic Ovary Syndrome to Metabolic Polyendocrine Ovary Syndrome, a title that finally honors the condition's systemic hormonal and metabolic complexity. The change, published in The Lancet, is both a scientific correction and a quiet reckoning — an admission that medicine, for decades, looked at these women and did not see the full picture.
- A name that pointed to ovarian cysts was quietly steering doctors away from the real crisis: a systemic hormonal and metabolic disorder affecting one in eight women worldwide.
- Millions of women spent years undiagnosed while symptoms like insulin resistance, irregular cycles, and abdominal weight gain were dismissed as ordinary features of womanhood.
- What were called cysts were not cysts at all — they were immature follicles, and the confusion embedded in that misidentification shaped decades of incomplete treatment.
- Fifty-six international organizations, drawing on input from over 14,000 patients and professionals, forged a new name — Metabolic Polyendocrine Ovary Syndrome — to match the condition's true clinical scope.
- Medical schools, health systems, and clinical guidelines now face a three-year transition to integrate the new terminology and the broader understanding of disease it demands.
For decades, one in eight women carried a diagnosis built on a fundamental misreading. Polycystic Ovary Syndrome — PCOS — implied the problem lived in the ovaries, a matter of cysts and reproductive function. But the name was wrong, and the wrongness had a cost. Symptoms that should have raised alarms — irregular periods, persistent acne, hair loss, abdominal weight gain, insulin resistance — were routinely normalized or attributed to other causes, leaving the deeper metabolic disorder unaddressed.
An international scientific consensus has now formally corrected this. The condition is no longer PCOS. It is Metabolic Polyendocrine Ovary Syndrome — a name that reflects what researchers have come to understand: this is a systemic endocrine and metabolic disease that affects the ovaries among many other systems, not a gynecological problem that happens to have side effects.
Sergio Wehinger of the Universidad de Talca explained that what appeared on ultrasounds as cysts were actually small immature follicles — a visual misreading that anchored a generation of incomplete diagnoses. The real disorder involves hormonal dysregulation, insulin resistance, and elevated metabolic risk that often went untreated precisely because the name directed attention elsewhere. Symptoms can emerge as early as adolescence, and early detection — including monitoring of Anti-Müllerian Hormone levels and family history — can prevent long-term complications.
The renaming emerged from a rigorous process involving 56 international organizations and more than 14,000 patients and healthcare professionals, with findings published in The Lancet. Full integration into medical education and clinical guidelines is expected to take roughly three years. The new name is more accurate — and it is also, quietly, an acknowledgment of all the years that accuracy was absent.
For decades, a condition affecting one in eight women carried a name that was fundamentally misleading. Polycystic Ovary Syndrome—PCOS—suggested the problem was straightforward: multiple cysts in the ovaries, a reproductive issue. But the name was wrong, and that wrongness had consequences. Women with the condition often went undiagnosed for years. Doctors missed the broader metabolic and hormonal chaos happening inside their bodies. Symptoms that should have triggered alarm—irregular periods, stubborn acne, hair loss, weight gain concentrated around the abdomen—were normalized, dismissed, absorbed into the background noise of being a woman.
Now, an international scientific consensus has formally renamed the condition. It is no longer PCOS. It is now Síndrome de Ovario Metabólico Poliendocrino, or SOMP—Metabolic Polyendocrine Ovary Syndrome. The change, published in The Lancet, reflects what researchers have come to understand: this is not primarily an ovarian disorder. It is a systemic endocrine and metabolic disease that happens to affect the ovaries, among many other systems in the body.
Sergio Wehinger, an academic at the Universidad de Talca's Faculty of Health Sciences, explained the distinction with precision. What doctors had been calling cysts were not actually cysts at all. They were small antral follicles—immature egg sacs—that appeared on ultrasound to look like cysts but were not. The real problem was not concentrated in the ovaries or limited to fertility. It was a much wider disorder of hormones and metabolism. The old name had done real damage by reducing the condition to a reproductive problem, which meant women with metabolic complications—insulin resistance, blood sugar dysregulation, elevated risk of diabetes—often went untreated for those aspects of their illness.
The symptoms of what is now called SOMP can appear as early as adolescence, though they are frequently dismissed or attributed to other causes. Persistent acne, hair loss, painful or irregular menstrual cycles, accumulation of fat in the abdomen—these are all warning signs. So are elevated levels of Anti-Müllerian Hormone in the blood, a marker that specialists now know to watch for. Family history matters too. Insulin resistance and difficulty managing blood sugar levels are often present. Early detection matters because it can prevent long-term metabolic and hormonal complications that might otherwise go unaddressed.
The renaming was not a casual decision. It emerged from a rigorous process involving 56 international organizations and input from more than 14,000 patients and healthcare professionals. The work reflects a shift in how the medical community understands this disease—not as a gynecological curiosity but as a systemic metabolic disorder that demands comprehensive treatment. Wehinger emphasized that the new name better captures the true clinical scope of the condition and should reduce the diagnostic confusion that has historically delayed care.
The integration of this new terminology into medical practice will not happen overnight. Universities, health systems, and clinical guidelines will need time to adopt it. The timeline is roughly three years. But the change signals something important: a recognition that women have been living with a condition that was not only misnamed but fundamentally misunderstood. The new name is more accurate. It is also, in a way, an acknowledgment of all the years that accuracy was missing.
Citas Notables
The old term was inexact and even erroneous, because it is not a syndrome in which the ovary has multiple cysts— Sergio Wehinger, Universidad de Talca
The problem is not concentrated only in the ovary or solely in fertility. It is a much broader endocrine and metabolic disorder— Sergio Wehinger, Universidad de Talca
La Conversación del Hearth Otra perspectiva de la historia
Why did the old name persist for so long if it was actually wrong?
Because it was based on what doctors could see on an ultrasound—follicles that looked like cysts. The visual evidence seemed to confirm the name. But seeing something on an image is not the same as understanding what it means. The condition is much more than what shows up in pictures.
So women were being treated for the wrong disease?
Not entirely. But they were being treated incompletely. If a doctor thought the problem was ovarian cysts, they might focus on fertility or ovarian function. They might miss the insulin resistance, the metabolic dysfunction, the hormonal imbalances that were causing real harm.
How many women are we talking about?
One in eight. That is tens of millions of women globally who have been living with a misnamed, misunderstood condition. Many of them normalized symptoms that should have been red flags.
What changes now, practically speaking?
The name change is the beginning. It signals to doctors that this is a metabolic disease, not just a reproductive one. It should prompt more comprehensive screening, earlier diagnosis, better treatment. But the real change depends on how quickly the medical system actually adopts the new understanding.
Is there resistance to the change?
Not that we see reported. The consensus involved 56 international organizations. But changing how an entire medical system thinks about and names a disease takes time. That is why they are planning for three years of integration into education and guidelines.